# Hepatitis C Re-Treatment Recommendations

If you have been treated for hepatitis C before, here are the recommendations for re-treatment for all genotypes from the American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA).

AASLD HCV Re-treatment Recommendations for People Who Failed Prior Peginterferon and Ribavirin Treatment without Decompensated Cirrhosis or Certain Co-existing Medical Conditions, such as HCV Recurrence Post-Liver Transplant (Medications are listed first by evidence level according to the HCVGuidelines.org, then listed alphabetically.)

<table>
<thead>
<tr>
<th>Genotype</th>
<th>no cirrhosis</th>
<th>compensated cirrhosis</th>
<th>no cirrhosis</th>
<th>compensated cirrhosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype 1a</td>
<td>Epclusa* for 12 weeks</td>
<td>Mavyret for 12 weeks</td>
<td>Daklinza + Sovaldi for 12 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Harvoni* for 12 weeks</td>
<td>Zepatier for 8 weeks</td>
<td>Zepatier + ribavirin for 16 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mavryet for 8 weeks (without baseline NS5A RASs**)</td>
<td></td>
<td>(with baseline NS5A RASs**)</td>
<td></td>
</tr>
<tr>
<td>Genotype 1a</td>
<td>Epclusa* for 12 weeks</td>
<td>Mavryet for 12 weeks</td>
<td>Daklinza + Sovaldi for 12 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Harvoni* for 12 weeks</td>
<td></td>
<td>Zepatier + ribavirin for 16 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mavryet for 12 weeks (without baseline NS5A RASs**)</td>
<td></td>
<td>(with baseline NS5A RASs**)</td>
<td></td>
</tr>
<tr>
<td>Genotype 1b</td>
<td>Epclusa* for 12 weeks</td>
<td>Mavryet for 8 weeks</td>
<td>Harvoni* + ribavirin for 12 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Harvoni* for 12 weeks</td>
<td></td>
<td>Zepatier + ribavirin for 16 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mavryet for 8 weeks</td>
<td></td>
<td>(with baseline NS5A RASs**)</td>
<td></td>
</tr>
<tr>
<td>Genotype 1b</td>
<td>Epclusa* for 12 weeks</td>
<td>Mavryet for 12 weeks</td>
<td>Daklinza + Sovaldi for 12 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Zepatier for 12 weeks</td>
<td></td>
<td>Zepatier + ribavirin for 16 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mavryet for 12 weeks</td>
<td></td>
<td>(with baseline NS5A RASs**)</td>
<td></td>
</tr>
<tr>
<td>Genotype 2</td>
<td>Epclusa* for 12 weeks</td>
<td>Mavryet for 8 weeks</td>
<td>Daklinza + Sovaldi for 12 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Harvoni* for 12 weeks</td>
<td></td>
<td>Zepatier + ribavirin for 16 weeks</td>
<td></td>
</tr>
<tr>
<td>Genotype 2</td>
<td>Epclusa* for 12 weeks</td>
<td>Mavryet for 12 weeks</td>
<td>Daklinza + Sovaldi for 16 to 24 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Harvoni* for 12 weeks</td>
<td></td>
<td>Zepatier + ribavirin for 16 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mavryet for 16 weeks</td>
<td></td>
<td>(with baseline NS5A RASs**)</td>
<td></td>
</tr>
<tr>
<td>Genotype 3</td>
<td>Epclusa* for 12 weeks</td>
<td>Mavryet for 12 weeks</td>
<td>Daklinza + Sovaldi for 12 weeks</td>
<td></td>
</tr>
</tbody>
</table>

*Recommended

**Alternative
<table>
<thead>
<tr>
<th>Geotype 3</th>
<th>Recommended</th>
<th>Alternative</th>
</tr>
</thead>
<tbody>
<tr>
<td>compensated cirrhosis</td>
<td>Zepatier + Sovaldi for 12 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Vosevi for 12 weeks</td>
<td>Epclusa* for 12 weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mavyret for 8 weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Harvoni* for 12 weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Zepatier for 12 weeks for responder-relapsers to prior treatment</td>
</tr>
<tr>
<td>Genotype 4</td>
<td></td>
<td>Zepatier + ribavirin for 16 weeks if prior treatment failed to suppress HCV</td>
</tr>
<tr>
<td>no cirrhosis</td>
<td>Epclusa* for 12 weeks</td>
<td>Harvoni* + ribavirin for 12 weeks</td>
</tr>
<tr>
<td></td>
<td>Mavyret for 12 weeks</td>
<td>Zepatier + ribavirin for 16 weeks</td>
</tr>
<tr>
<td></td>
<td>Harvoni* for 12 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Genotype 4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>compensated cirrhosis</td>
<td>Epclusa* for 12 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mavyret for 12 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Zepatier for 12 weeks for responder-relapsers to prior treatment</td>
<td></td>
</tr>
<tr>
<td>Genotype 5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>no cirrhosis</td>
<td>Epclusa* for 12 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Harvoni* for 12 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mavyret for 8 weeks</td>
<td></td>
</tr>
<tr>
<td>Genotype 5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>compensated cirrhosis</td>
<td>Mavyret for 12 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Epclusa* for 12 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Harvoni* for 12 weeks</td>
<td></td>
</tr>
<tr>
<td>Genotype 6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>no cirrhosis</td>
<td>Epclusa* for 12 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Harvoni* for 12 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mavyret for 8 weeks</td>
<td></td>
</tr>
<tr>
<td>Genotype 6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>compensated cirrhosis</td>
<td>Mavyret for 12 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Epclusa* for 12 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Harvoni* for 12 weeks</td>
<td></td>
</tr>
</tbody>
</table>

**Genotype 1a**

<table>
<thead>
<tr>
<th>no cirrhosis</th>
<th>Recommended</th>
<th>Alternative</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Epclusa* for 12 weeks</td>
<td>Daklinza + Sovaldi for 12 weeks</td>
</tr>
<tr>
<td></td>
<td>Harvoni* for 12 weeks</td>
<td>Zepatier + ribavirin for 16 weeks (with baseline NS5A RASs**)</td>
</tr>
<tr>
<td></td>
<td>Mavyret for 8 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Zepatier for 12 weeks (without baseline NS5A RASs**)</td>
<td></td>
</tr>
</tbody>
</table>

**Genotype 1a**

<table>
<thead>
<tr>
<th>compensated cirrhosis</th>
<th>Recommended</th>
<th>Alternative</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Epclusa* for 12 weeks</td>
<td>Harvoni* + ribavirin for 12 weeks</td>
</tr>
<tr>
<td></td>
<td>Zepatier for 12 weeks (without baseline NS5A RASs**)</td>
<td>Zepatier + ribavirin for 16 weeks (with baseline NS5A RASs**)</td>
</tr>
<tr>
<td></td>
<td>Mavyret for 12 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Genotype 1b**

**no cirrhosis**

- **Recommended**
  - Epclusa* for 12 weeks
  - Harvoni* for 12 weeks
  - Mavyret for 8 weeks
  - Zepatier for 12 weeks

- **Alternative**
  - Daklinza + Sovaldi for 12 weeks

**Genotype 1b**

**compensated cirrhosis**

- **Recommended**
  - Epclusa* for 12 weeks
  - Zepatier for 12 weeks
  - Mavyret for 12 weeks

- **Alternative**
  - Harvoni* + ribavirin for 12 weeks

**Genotype 2**

**no cirrhosis**

- **Recommended**
  - Epclusa* for 12 weeks
  - Mavyret for 8 weeks

- **Alternative**
  - Daklinza + Sovaldi for 12 weeks

**Genotype 2**

**compensated cirrhosis**

- **Recommended**
  - Epclusa* for 12 weeks
  - Mavyret for 12 weeks

- **Alternative**
  - Daklinza + Sovaldi for 16 to 24 weeks

**Genotype 3**

**no cirrhosis**

- **Recommended**
  - Epclusa* for 12 weeks
  - Daklinza + Sovaldi for 12 weeks
  - Mavyret for 16 weeks
  - Vosevi for 12 weeks (with Y93H RASs**)

- **Alternative**
  - Mavyret for 16 weeks

**Genotype 3**

**compensated cirrhosis**

- **Recommended**
  - Zepatier + Sovaldi for 12 weeks

- **Alternative**
  - Epclusa* + ribavirin for 12 weeks
  - Mavyret for 16 weeks

**Genotype 4**

**no cirrhosis**

- **Recommended**
  - Epclusa* for 12 weeks
  - Mavyret for 8 weeks
  - Harvoni* for 12 weeks
  - Zepatier for 12 weeks for responder-relapsers to prior treatment

- **Alternative**
  - Zepatier + ribavirin for 16 weeks if prior treatment failed to suppress HCV
Geontype 4
compensated cirrhosis

**Recommended**
- Epclusa* for 12 weeks
- Mavyret for 12 weeks
- Zepatier for 12 weeks for responder-relapsers to prior treatment

**Alternative**
- Harvoni* + ribavirin for 12 weeks
- Zepatier + ribavirin for 16 weeks if prior treatment failed to suppress HCV

Genotype 5
no cirrhosis

**Recommended**
- Epclusa* for 12 weeks
- Harvoni* for 12 weeks
- Mavyret for 8 weeks

Genotype 5
compensated cirrhosis

**Recommended**
- Mavyret for 12 weeks
- Epclusa* for 12 weeks
- Harvoni* for 12 weeks

Genotype 6
no cirrhosis

**Recommended**
- Epclusa* for 12 weeks
- Harvoni* for 12 weeks
- Mavyret for 8 weeks

Genotype 6
compensated cirrhosis

**Recommended**
- Mavyret for 12 weeks
- Epclusa* for 12 weeks
- Harvoni* for 12 weeks

*Generic version is available in the United States.

**RASs = resistance-associated substitutions (formerly RAVs or resistance-associated variants)

AASLD HCV Re-treatment Recommendations for People Who Failed Prior Treatment with Peginterferon, Ribavirin, and an HCV NS3 Protease Inhibitor (Incivek, Olysio, Victrelis)

(Medications are listed first by evidence level according to the [HCVGuidelines.org](http://HCVGuidelines.org), then listed alphabetically.)
### AASLDHCV Re-treatment Recommendations for People Who Failed Prior Non-NS5A Inhibitor Treatment Containing Sovaldi

(Medications are listed first by evidence level according to the [HCVGuidelines.org](https://www.hcvguidelines.org), then listed alphabetically.)

<table>
<thead>
<tr>
<th>Genotype</th>
<th>Recommended</th>
<th>Alternative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype 1 no cirrhosis</td>
<td>- Vosevi for 12 weeks</td>
<td>- Harvoni* + ribavirin for 12 weeks (except when previously failed Olysio treatment)</td>
</tr>
<tr>
<td>Genotype 1 compensated cirrhosis</td>
<td>- Vosevi for 12 weeks</td>
<td>- Harvoni* + ribavirin for 12 weeks (except when previously failed Olysio treatment)</td>
</tr>
<tr>
<td>Genotype 2 no cirrhosis</td>
<td>- Epclusa* for 12 weeks</td>
<td></td>
</tr>
<tr>
<td>Genotype 2 compensated cirrhosis</td>
<td>- Epclusa* for 12 weeks</td>
<td></td>
</tr>
<tr>
<td>Genotype 3</td>
<td>no cirrhosis</td>
<td>Recommended</td>
</tr>
<tr>
<td>------------</td>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Genotype 3</td>
<td>compensated cirrhosis</td>
<td>Vosevi for 12 weeks</td>
</tr>
<tr>
<td>Genotype 4</td>
<td>no cirrhosis</td>
<td>Vosevi for 12 weeks</td>
</tr>
<tr>
<td>Genotype 4</td>
<td>compensated cirrhosis</td>
<td>Vosevi for 12 weeks</td>
</tr>
<tr>
<td>Genotype 5 or 6</td>
<td>no cirrhosis</td>
<td>Vosevi for 12 weeks</td>
</tr>
<tr>
<td>Genotype 5 or 6</td>
<td>compensated cirrhosis</td>
<td>Vosevi for 8 weeks</td>
</tr>
</tbody>
</table>

Genotype 1
no cirrhosis
Recommended
- Vosevi for 12 weeks
- Epclusa* for 12 weeks
- Mavyret for 12 weeks
Alternative
- Harvoni* + ribavirin for 12 weeks (except when previously failed Olysio treatment)

Genotype 1
compensated cirrhosis
Recommended
- Vosevi for 12 weeks
- Epclusa* for 12 weeks
- Mavyret for 12 weeks
Alternative

Genotype 2
no cirrhosis
Recommended
- Epclusa* for 12 weeks
- Mavyret for 12 weeks
Alternative

Genotype 2
compensated cirrhosis
Recommended
- Epclusa* for 12 weeks
- Mavyret for 12 weeks
Alternative

Genotype 3
no cirrhosis
Recommended
- Vosevi for 12 weeks
Alternative
Genotype 3 
compensated cirrhosis
Recommended • Vosevi + ribavirin for 12 weeks
Alternative

Genotype 4 
no cirrhosis
Recommended • Vosevi for 12 weeks
Alternative

Genotype 4 
compensated cirrhosis
Recommended • Vosevi for 12 weeks
Alternative

Genotype 5 or 6 
no cirrhosis
Recommended • Vosevi for 8 weeks
Alternative

Genotype 5 or 6 
compensated cirrhosis
Recommended • Vosevi for 12 weeks
Alternative

*Generic version is available in the United States.

AASLD HCV Re-treatment Recommendations for People Who Failed Prior Treatment with an NS5A Inhibitor Direct-Acting Antiviral (DAA) (Medications are listed first by evidence level according to the HCVGuidelines.org, then listed alphabetically.)

Genotype 1 
no cirrhosis or compensated cirrhosis
Recommended • Vosevi for 12 weeks
Alternative • Mavyret for 16 weeks (except if previously treated with NS3/4 protease inhibitor DAA)

Genotype 3 
no cirrhosis or compensated cirrhosis
Recommended • Vosevi for 12 weeks (+ ribavirin if cirrhosis and prior NS5A failure)

Genotype 4, 5, 6 
no cirrhosis or compensated cirrhosis
Recommended • Vosevi for 12 weeks
**Genotype 1**

*no cirrhosis or compensated cirrhosis*

**Recommended**  • Vosevi for 12 weeks

**Alternative**  • Mavyret for 16 weeks (except if previously treated with NS3/4 protease inhibitor DAA)

---

**Genotype 3**

*no cirrhosis or compensated cirrhosis*

**Recommended**  • Vosevi for 12 weeks (+ ribavirin if cirrhosis and prior NS%A failure)

**Alternative**

---

**Genotype 4, 5, 6**

*no cirrhosis or compensated cirrhosis*

**Recommended**  • Vosevi for 12 weeks

**Alternative**

---

For those needing information about medication for advanced liver disease, visit [HCV treatment recommendations for those with decompensated cirrhosis](https://www.hepmag.com/basics/hepatitis-c-basics/hepatitis-c-retreatment-recommendations). Click on [HCV Treatment Post-Transplantation](https://www.hepmag.com/basics/hepatitis-c-basics/hepatitis-c-retreatment-recommendations) for information about HCV recurrence following liver transplantation.

Last Reviewed: March 11, 2019

© 2020 Smart + Strong All Rights Reserved.  